Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Saronno – page 202

2 862 clinical trials in Saronno, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Saronno at a glance
2 862
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 862 trials in Saronno

Open in trial search

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Brain stem glioma

Not recruiting

Study on Radiotherapy with Nimotuzumab and Vinorelbine for Newly Diagnosed Childhood and Adolescent Diffuse Intrinsic Pontine Glioma (DIPG) Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Nimotuzumab
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Study on Health, Activity, and Joint Outcomes in Patients Aged 13-69 with Severe or Moderate Hemophilia A Using Emicizumab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Myasthenia gravis

Not recruiting

Study on the Effects of Iptacopan in Patients with Generalized Myasthenia Gravis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Colitis ulcerative

Not recruiting

Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Tofacitinib
  • Sponsor:Pfizer Inc.

Study on BP1.7881 for Adults with Eosinophilic Esophagitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Bioprojet Pharma

Study of Cemiplimab Compared to Placebo After Surgery and Radiation for Patients with High-Risk Skin Squamous Cell Carcinoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Long-term Safety and Efficacy Study of Onasemnogene Abeparvovec in Patients with Spinal Muscular Atrophy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Dimethyl Fumarate
  • Sponsor:Novartis Pharma AG

Neoplasm malignant+1

Not recruiting

Study of Entrectinib for Patients with Advanced or Metastatic Solid Tumors with Specific Gene Changes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Entrectinib
  • Sponsor:F. Hoffmann-La Roche AG
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study on the Effectiveness and Safety of Cevostamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Saronno

What the registry says about research in the country

01 Respiratory Oncology

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, including studies evaluating novel therapeutic approaches for patients with specific genetic mutations.

  • MET deregulation therapy assessment
  • Second-line combination treatments
  • EGFR mutation targeting

Research emphasizes personalized treatment strategies for advanced and metastatic disease states.

02 Women's Oncology

Comprehensive studies addressing breast cancer and gynecological malignancies, with focus on treatment timing and maintenance therapies.

  • Endocrine-responsive breast cancer treatment
  • Ovarian cancer maintenance therapy
  • BRCA wild-type cancer management

Investigations aim to optimize treatment sequences and improve patient outcomes.

03 Specialized Oncology & Cardiology

Innovative research in renal cell carcinoma treatment and cardiac conditions, particularly focusing on novel therapeutic approaches.

  • Metastatic renal cancer therapy
  • Atrial fibrillation management
  • Targeted combination therapies

Studies evaluate both oncological interventions and cardiovascular treatments for high-risk patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.